Caribou Biosciences (CRBU) Total Non-Current Liabilities (2020 - 2022)

Caribou Biosciences (CRBU) has 3 years of Total Non-Current Liabilities data on file, last reported at $72.9 million in Q4 2022.

• On a quarterly basis, Total Non-Current Liabilities rose 33.72% year-over-year to $72.9 million in Q4 2022; TTM through Dec 2022 was $72.9 million, a 33.72% increase from a year earlier, with the FY2022 full-year figure at $72.9 million, up 33.72% from the prior year.
• Total Non-Current Liabilities for Q4 2022 stood at $72.9 million, down from $74.7 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for CRBU reached as high as $74.7 million in Q3 2022 and fell as low as $18.0 million in Q4 2020.
• Historically, Total Non-Current Liabilities has averaged $60.1 million across 3 years, with a median of $65.1 million in 2021.
• Across the five-year window, Total Non-Current Liabilities jumped 203.12% in 2021 and soared 30.14% in 2022, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $18.0 million in 2020, then soared by 203.12% to $54.5 million in 2021, then jumped by 33.72% to $72.9 million in 2022.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $72.9 million in Q4 2022, $74.7 million in Q3 2022, and $73.5 million in Q2 2022.